EWTX:NASDAQ, Edgewise Therapeutics, Inc.

EWTX stock overview

Edgewise Therapeutics, Inc. (EWTX:NASDAQ) closed at $39.65 on October 21, 2026, down 0.25% on the day. The stock trades 18.3% below its 52-week high of $48.51 and 170.2% above its 52-week low of $14.68. Over the past year, it gained 167.0%. Edgewise Therapeutics, Inc. is part of the Health Care sector.

Key figures

Price: $39.65
Day change: -0.25%
Volume: 1,828,338
Average volume: 1,414,346
Market cap: 4B+
52-week range: $14.68 – $48.51
50-day average: $42.08
200-day average: $35.69

Price action over the past year

In 252 trading sessions since October 21, 2025, EWTX closed higher on 119 days (47%). Its best day was December 24, 2025 (+25.50%) and its worst was December 22, 2025 (-18.04%). The stock moved 10% or more in a single session 10 times. It opened at least 5% above the previous day's high 3 times.

Recent signals

Oct 21, 2026: News catalyst: Biotech (News Catalysts scanner)
Oct 21, 2026: Trading sideways between $36.28 and $39.75 over 14 days (Sideways scanner)
Oct 21, 2026: Hit a new 2-Week High of $39.75 (New Highs/Lows scanner)

EWTX news

Oct 21, 2026: William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
Oct 19, 2026: Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?
Oct 15, 2026: Does Edgewise Therapeutics' (EWTX) HFpEF Expansion Quietly Redefine Its Core Cardiovascular Strategy?
Oct 8, 2026: Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
Oct 3, 2026: Edgewise Therapeutics (EWTX) Sets EDG 7500 Focus Call, Is It Still 20% Below Fair Value?
Oct 2, 2026: Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?
Oct 1, 2026: Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Sep 25, 2026: Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says

About Edgewise Therapeutics, Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.

Similar stocks

Find more stocks like EWTX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.